

# Hiromichi Suzuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7867683/publications.pdf>

Version: 2024-02-01

66  
papers

2,595  
citations

361296

20  
h-index

197736

49  
g-index

73  
all docs

73  
docs citations

73  
times ranked

4567  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): A prospective observational study with nasopharyngeal samples. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 78-81.	0.8	8
2	Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 248-251.	0.8	10
3	A prospective clinical evaluation of the diagnostic accuracy of the SARS-CoV-2 rapid antigen test using anterior nasal samples. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 780-785.	0.8	7
4	Case of Moxifloxacin-Induced Black Hairy Tongue. <i>American Journal of Case Reports</i> , 2022, 23, e936235.	0.3	6
5	A prospective evaluation of diagnostic performance of a combo rapid antigen test QuickNavi-Flu+COVID19 Ag. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 840-843.	0.8	17
6	Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in Nasal Samples. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 323-331.	1.6	8
7	Clinical evaluation of the rapid nucleic acid amplification point-of-care test (Smart Gene SARS-CoV-2) in the analysis of nasopharyngeal and anterior nasal samples. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 543-547.	0.8	13
8	Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1045-1083.	0.8	15
9	Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study. <i>Scientific Reports</i> , 2021, 11, 10519.	1.6	34
10	A Prospective Evaluation of the Analytical Performance of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 495-504.	1.6	18
11	The evaluation of a newly developed antigen test (QuickNavi, COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 890-894.	0.8	41
12	Prospective analytical performance evaluation of the QuickNavi, COVID19 Ag for asymptomatic individuals. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1489-1492.	0.8	17
13	The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1493-1497.	0.8	15
14	Influence of Illness Duration on the Sensitivity and Specificity of Influenza Antigen Testing: A Prospective Observational Study Using Real-time PCR. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2021, 95, 9-16.	0.0	1
15	Results of the 1 <sup>st</sup> Questionnaire Survey on the Gastrointestinal Infection. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2021, 95, 117-121.	0.0	0
16	The evaluation of the utility of the GENECUBE HQ SARS-CoV-2 for anterior nasal samples and saliva samples with a new rapid examination protocol. <i>PLoS ONE</i> , 2021, 16, e0262159.	1.1	7
17	Clinical evaluation of a non-purified direct molecular assay for the detection of Clostridioides difficile toxin genes in stool specimens. <i>PLoS ONE</i> , 2020, 15, e0234119.	1.1	5
18	Evaluation of GENECUBE Mycoplasma for the detection of macrolide-resistant Mycoplasma pneumoniae. <i>Journal of Medical Microbiology</i> , 2020, 69, 1346-1350.	0.7	12

#	ARTICLE	IF	CITATIONS
19	Results of the Second Questionnaire Survey on the Genetic Testing for Infectious Diseases. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 297-303.	0.0	0
20	Evaluation of performance of the GENECUBE assay for rapid molecular identification of Staphylococcus aureus and methicillin resistance in positive blood culture medium. PLoS ONE, 2019, 14, e0219819.	1.1	16
21	Glomerular solidification is associated with nephritis-related clinical parameters in IgA nephropathy. Renal Failure, 2019, 41, 893-898.	0.8	0
22	Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus. Journal of Infection and Chemotherapy, 2019, 25, 578-583.	0.8	16
23	Implementation of Point-of-Care Molecular Diagnostics for <i>Mycoplasma pneumoniae</i> Ensures the Correct Antimicrobial Prescription for Pediatric Pneumonia Patients. Tohoku Journal of Experimental Medicine, 2018, 246, 225-231.	0.5	7
24	Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. Journal of Infection and Chemotherapy, 2018, 24, 907-914.	0.8	18
25	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	9.4	348
26	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	0.6	64
27	Prospective intervention study with a microarray-based, multiplexed, automated molecular diagnosis instrument (Verigene system) for the rapid diagnosis of bloodstream infections, and its impact on the clinical outcomes. Journal of Infection and Chemotherapy, 2015, 21, 849-856.	0.8	52
28	Effects of cell-type-specific expression of a pan-caspase inhibitor on renal fibrogenesis. Clinical and Experimental Nephrology, 2015, 19, 350-358.	0.7	3
29	Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia. Journal of Infection and Chemotherapy, 2015, 21, 596-603.	0.8	8
30	The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney International, 2015, 87, 233-238.	2.6	84
31	Impact of intensive infection control team activities on the acquisition of methicillin-resistant Staphylococcus aureus, drug-resistant Pseudomonas aeruginosa and the incidence of Clostridium difficile-associated disease. Journal of Infection and Chemotherapy, 2013, 19, 1047-1052.	0.8	11
32	Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genetics, 2013, 45, 860-867.	9.4	955
33	Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. CKJ: Clinical Kidney Journal, 2009, 2, 192-193.	1.4	9
34	Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. Clinical and Experimental Nephrology, 2008, 12, 102-109.	0.7	52
35	Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial. American Journal of Kidney Diseases, 2008, 52, 501-506.	2.1	173
36	Viruses may trigger allopurinol hypersensitivity syndrome. CKJ: Clinical Kidney Journal, 2008, 1, 273-274.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Association of ecNOS gene polymorphisms with end stage renal diseases. <i>Molecular and Cellular Biochemistry</i> , 2003, 244, 113-118.	1.4	48
38	Biophysical Signals Underlying Myogenic Responses in Rat Interlobular Artery. <i>Hypertension</i> , 1998, 32, 1060-1065.	1.3	22
39	Increased Intracellular Ca <sup>2+</sup> is Not Coinherited With an Inferred Major Gene Locus for Hypertension (ht) in the Spontaneously Hypertensive Rat. <i>American Journal of Hypertension</i> , 1997, 10, 282-288.	1.0	13
40	Does Combined Therapy of Ca-channel Blocker and Angiotensin Converting Enzyme Inhibitor Exceed Monotherapy in Renal Protection Against Hypertensive Injury in Rats?. <i>Clinical and Experimental Hypertension</i> , 1996, 18, 243-256.	0.5	6
41	Comparison of Early and Late Start of Antihypertensive Agents and Baroreceptor Reflexes. <i>Hypertension</i> , 1996, 27, 209-218.	1.3	20
42	Modulation of Angiotensin II Type 1 Receptor mRNA Expression in Human Blood Cells: Comparison of Platelets and Mononuclear Leucocytes.. <i>Endocrine Journal</i> , 1995, 42, 15-22.	0.7	30
43	Systemic lupus erythematosus: A follow-up study of Japanese patients with end-stage renal failure treated with haemodialysis. <i>Nephrology</i> , 1995, 1, 527-533.	0.7	0
44	AUGMENTED Ca <sup>2+</sup> MOBILIZATION IS A HYPERTENSIVE TRAIT DISCRIMINATED FROM A ?MAJOR GENE? IN BACKCROSS ANALYSIS BETWEEN SHR AND DONRYU RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, S220-S222.	0.9	2
45	BARORECEPTOR FUNCTION IS RESTORED BY ANTIHYPERTENSIVE THERAPY THROUGH LOWERING OF BLOOD PRESSURE IN ADULT SHR. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, S67-S69.	0.9	3
46	Nitric Oxide Modulates but Does Not Impair Myogenic Vasoconstriction of the Afferent Arteriole in Spontaneously Hypertensive Rats. <i>Hypertension</i> , 1995, 25, 1212-1219.	1.3	39
47	Differential Modulation of Baroreceptor Sensitivity by Long-term Antihypertensive Treatment. <i>Hypertension</i> , 1995, 26, 425-431.	1.3	12
48	Gene Expression of Angiotensin II Receptor in Blood Cells of Cushingâ€™s Syndrome. <i>Hypertension</i> , 1995, 26, 1003-1010.	1.3	21
49	The Effects of Chronic, and Selective Vasopressin Receptor Blockade in Spontaneously Hypertensive Rats. <i>International Heart Journal</i> , 1995, 36, 538-538.	0.6	0
50	Effects of Vasopressin V1 and V2 Receptor Antagonists on Progressive Renal Failure in Rats. <i>Clinical Science</i> , 1994, 86, 399-404.	1.8	29
51	Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 413-420.	1.3	27
52	Enzymuria in Non-Insulin-Dependent Diabetic Patients: Signs of Tubular Cell Dysfunction. <i>Clinical Science</i> , 1993, 84, 469-475.	1.8	43
53	Increases in NO <sup>2+</sup> /NO <sup>3+</sup> excretion in the urine as an indicator of the release of endothelium-derived relaxing factor during elevation of blood pressure. <i>Clinical Science</i> , 1992, 82, 631-634.	1.8	59
54	Effects of l-arginine on systemic and renal haemodynamics in conscious dogs. <i>Clinical Science</i> , 1991, 81, 727-732.	1.8	23

#	ARTICLE	IF	CITATIONS
55	Pressor and hormonal responses to intravenous injection of metoclopramide in normotensive and hypertensive patients.. Japanese Journal of Medicine, 1990, 29, 174-179.	0.1	1
56	Benidipine. Cardiovascular Drug Reviews, 1989, 7, 25-38.	4.4	5
57	Differences in the effects of angiotensin converting enzyme inhibitors with or without a thiol group in chronic renal failure in rats. Clinical Science, 1989, 76, 353-356.	1.8	15
58	Effects of Endothelin on Systemic and Renal Haemodynamics and Neuroendocrine Hormones in Conscious Dogs. Clinical Science, 1989, 77, 567-572.	1.8	41
59	The influence of dietary protein on the synthesis of vasoactive substances in subtotally nephrectomized spontaneously hypertensive rats.. International Heart Journal, 1989, 30, 917-927.	0.6	0
60	Characterization of neurohormonal changes following the production of the benign and malignant phases of two-kidney, two-clip Goldblatt hypertension.. International Heart Journal, 1987, 28, 413-426.	0.6	7
61	Changes in central and peripheral renin-angiotensin system after furosemide injection.. Endocrinologia Japonica, 1986, 33, 497-503.	0.5	5
62	effects of Calcium Loading on Blood Pressure in Spontaneously Hypertensive Rats:attenuation of the vascular reactivity. Clinical and Experimental Hypertension, 1986, 8, 355-370.	0.3	12
63	Effects of magnesium on the vasoconstrictor responses to norepinephrine and potassium chloride in the rat mesenteric artery.. International Heart Journal, 1982, 23, 783-789.	0.6	0
64	Dexamethasone Hypertension in Rats. Clinical and Experimental Hypertension, 1981, 3, 1075-1086.	1.2	27
65	Effects of captopril and prostaglandin I2 on vasocnstrictor responses to norepinephrine and potassium ions in rat mesenteric artery.. International Heart Journal, 1981, 22, 617-625.	0.6	3
66	Vascular action of high dose estrogen in rats.. Endocrinologia Japonica, 1980, 27, 307-313.	0.5	20